**Digoxin-Like Immunoreactive Substance in Renal Failure**

<table>
<thead>
<tr>
<th>N.</th>
<th>Neslihan Seyrek</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.</td>
<td>Saime Paydas</td>
</tr>
<tr>
<td>Ö.</td>
<td>Özoğul Sargin</td>
</tr>
<tr>
<td>V.</td>
<td>Vedat Günday</td>
</tr>
<tr>
<td>Y.</td>
<td>Yahya Sağluker</td>
</tr>
</tbody>
</table>

**Departments of Nephrology and Nuclear Medicine, Faculty of Medicine, Çukurova University, Adana, Turkey**

Saime Paydas, MD, Department of Internal Medicine, Faculty of Medicine, Çukurova University, TR-01330 Adana (Turkey)

Table 1. Characteristics of patients and controls

Table 2. Correlation of serum digoxin and digitoxin levels with urea, Cr, Ccr, blood pressure, heart failure and edema analysis by RIA (kit: Coat-A-Count Diagnostic Products Corporation, Los Angeles, Calif., USA). Student’s t test and Pearson correlation were used for statistical evaluation.

Table 1 shows the characteristics of patients and controls. There was no significant difference in the mean serum digoxin level between the patients and healthy controls, but the mean serum digitoxin values were found.

Dear Sir,

The cardiac glycosides digoxin and digitoxin are important drugs in the management of heart failure and arrhythmias, and can be measured by radioimmunoassay (RIA) in serum and urine. It is known that cardiac glycosides have a high toxicity and narrow therapeutic ranges (usually 0.8-2.0 ng/ml) [1]. It has recently been reported that detectable levels of digoxin-like immunoreactive substance (DLIS) are found in third trimester pregnant women, neonates, patients with liver disease, patients with acute and chronic renal failure, hemodialysis patients and normal subjects [2-7]. These studies show that monitoring cardiac glycoside concentrations in serum is an important and useful measurement in patients with renal failure.

We measured DLIS in the serum of renal failure patients and normal subjects.

Patients, Methods and Results

Serum samples were obtained from 51 patients (23 males, 28 females) and from 25 healthy controls (13 males, 12 females). None of the patients or controls were receiving any cardiac glycosides. Patients had various nephropathies: essential hypertension 38 cases; chronic glomerulonephritis 4 cases; chronic tubulointerstitial nephropathy 5 cases; diabetic nephropathy 3 cases, and amyloidosis 1 case. We assessed hematocrit, white blood cell, sedimentation, blood urea nitrogen, serum creatinine (Cr) and creatinine clearance (Ccr) in patients and healthy controls. We recorded whether patients had heart failure or not. Blood samples were stored at -20°C until

Urea, mg/dl Cr, mg/dl Ccr, ml/min Systolic blood
pressure, mm Hg  Diastolic blood pressure, mm Hg  

0.3847 p < 0.01  0.2010 p > 0.05  
0.3620 p < 0.01  0.1853 p > 0.05  
-0.3167 p < 0.05  -0.4525 p > 0.01  
0.2802 p < 0.05  0.2104 p > 0.05  
0.2444 p < 0.05  0.1966 p > 0.05  

Edema and heart failure 0.2275 p < 0.05  0.0877 p > 0.05  
to be significantly higher in the patients than those in the healthy controls (table 2).  
Heart failure and edema were detected in 17 patients. Six patients had a Ccr of under 20  
ml/min, and the remaining patients more than 50 ml/min. In patients digoxin correlated  
directly with blood pressure, urea, Cr and edema, and digoxin and digitoxin correlated  
inversely with Ccr (table 2).  

Discussion  
DLIS, causing falsely raised plasma digoxin concentrations, has been reported in pregnant  
women, neonates, patients with liver disease and patients with acute and chronic renal failure  
(2–7). Our study shows that DLIS correlated directly with blood pressure, urea, Cr and  
inversely with Ccr. DLIS is believed to be water-soluble and heat-stable, with a molecular  
weight of less than 1,000 daltons. DLIS is present in serum and carried in plasma by albumin [2]. Some  
authors reported that DLIS represents a volume-sensitive factor like atrial natriuretic factor  
[8–10]. However, the exact structure and physiological importance of DLIS is still unknown.  
Cardiovascular disease often affects patients with renal failure and leads to mortality in these  
patients. The presence of DLIS in this population may pose serious problems in in- 
terpreting the plasma digoxin concentrations [11]. Our observations indicate that digoxin  
pharmacokinetics are altered minimally in renal failure patients.  
In conclusion, we found high plasma levels of DLIS in patients with edema, hypertension and  
lower Ccr. Therefore DLIS was considered as a volume-sensitive factor.  

References  
Valdes R Jr: Endogenous digoxin-like immunoreactive factor: Impact on digoxin  
Graves SW, Valdes R Jr, Brown BA, Knight AB, Craig HR: Endogenous digoxin- 
immunoreactive substance in human pregnancies. J Clin Endocrinol Metab 1984;58:748- 
751.  
Valdes RJ, Graves SW, Brown BA, Landt M: Endogenous substance in newborn infants  
Nanji AA, Greenway DC: Falsely resided plasma digoxin concentrations in liver disease. Br  
Gruber KA, Whitaker JM, Buckalev VM Jr: Endogenous digitalis-like substance in plasma of  

Seyrek/Paydas/Sargin/Günday/Saghker
Digoxin-Like Substance